Stable profit estimate this year, turnover in line with 2013 (Il Sole 24 Ore Radiocor) – Ingelheim, 15 April – Boehringer Ingelheim (BI), the German pharmaceutical company among the top twenty in the world, intends to grow "organically, sustainable, in the long term and standing alone". Also excluded are "major acquisitions". Thus the president Andreas Barner, who speaking to journalists on the sidelines of the budget meeting, forecast for this year a "more or less stable" profit compared to 2013 (1.32 billion) and a turnover "similar" to the last year (14.1 billion). After launching 3 new products and 8 filings in 2013, BI plans to launch more than 10 new drugs by 2016 for eight diseases: diabetes, chronic obstructive pulmonary disease, asthma, lung cancer, idiopathic pulmonary fibrosis, a rare form of leukemia and the treatment and prevention of deep vein thrombosis and pulmonary embolism.
pal-(RADIOCOR) 15-04-14 14:57:14 (0399) 5 NNNN The sun24 HOURS
